Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML

被引：0
|
作者：
Mushtaq, Rao [1 ]
Akbar, Faisal [2 ]
Khan, Israa [3 ]
Isom, Scott [4 ]
Pardee, Timothy [4 ]
Howard, Dianna S. [4 ]
Powell, Bayard L. [4 ]
机构：
[1] Univ Colorado, Aurora, CO USA
[2] Wake Forest Univ, Dept Med, Lewisville, NC USA
[3] Univ Colorado, Sch Med, Childrens Hosp Colorado, Dept Pediat Hosp Med, Aurora, CO USA
[4] Wake Forest Baptist Hlth, Comprehens Canc Ctr, Winston Salem, NC USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-110191
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5199
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study
    Baranwal, Anmol
    Chhetri, Rakchha
    Yeung, David
    Clark, Matthew
    Shah, Syed
    Litzow, Mark R.
    Hogan, William J. J.
    Mangaonkar, Abhishek
    Alkhateeb, Hassan B. B.
    Singhal, Deepak
    Cibich, Alia
    Bardy, Peter
    Kok, Chung H. H.
    Hiwase, Devendra K. K.
    Shah, Mithun Vinod
    BONE MARROW TRANSPLANTATION, 2023, 58 (07) : 769 - 776
  • [22] Prognostic relevance of myelodysplasia in de novo and secondary AML.
    Schaekel, U
    Brocard, B
    Kroschinsky, F
    Schaich, M
    Soucek, S
    Neubauer, A
    Ehninger, G
    BLOOD, 2000, 96 (11) : 106A - 106A
  • [23] De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
    Matheus Rodrigues Lopes
    João Kleber Novais Pereira
    Paula de Melo Campos
    João Agostinho Machado-Neto
    Fabiola Traina
    Sara T. Olalla Saad
    Patricia Favaro
    Scientific Reports, 7
  • [24] De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
    Lopes, Matheus Rodrigues
    Novais Pereira, Joao Kleber
    Campos, Paula de Melo
    Machado-Neto, Joao Agostinho
    Traina, Fabiola
    Olalla Saad, Sara T.
    Favaro, Patricia
    SCIENTIFIC REPORTS, 2017, 7
  • [25] Comparison of outcomes of HCT in blast phase of BCR-ABL1- MPN with de novo AML and with AML following MDS
    Gupta, Vikas
    Kim, Soyoung
    Hu, Zhen-Huan
    Liu, Ying
    Aljurf, Mahmoud
    Bacher, Ulrike
    Beitinjaneh, Amer
    Cahn, Jean-Yves
    Cerny, Jan
    Copelan, Edward
    Gadalla, Shahinaz M.
    Gale, Robert Peter
    Ganguly, Siddhartha
    George, Biju
    Gerds, Aaron T.
    Gergis, Usama
    Hamilton, Betty K.
    Hashmi, Shahrukh
    Hildebrandt, Gerhard C.
    Kamble, Rammurti T.
    Kindwall-Keller, Tamila
    Lazarus, Hillard M.
    Liesveld, Jane L.
    Litzow, Mark
    Maziarz, Richard T.
    Nishihori, Taiga
    Olsson, Richard F.
    Rizzieri, David
    Savani, Bipin N.
    Seo, Sachiko
    Solh, Melhem
    Szer, Jeff
    Verdonck, Leo F.
    Wirk, Baldeep
    Woolfrey, Ann
    Yared, Jean A.
    Alyea, Edwin P.
    Popat, Uday R.
    Sobecks, Ronald M.
    Scott, Bart L.
    Nakamura, Ryotaro
    Saber, Wael
    BLOOD ADVANCES, 2020, 4 (19) : 4748 - 4757
  • [26] MYC Expression Is Prognostic in Therapy Related Acute Myeloid Leukemia (AML) and AML with Myelodysplastic Syndrome (MDS)-Related Changes
    Ohanian, Maro
    Rozovski, Uri
    Kantarjian, Hagop M.
    Loghavi, Sanam
    Huh, Yang O.
    Abruzzo, Lynne
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Andreeff, Michael
    Kornblau, Steven M.
    Borthakur, Gautam
    Nguyen, Martin
    Stingo, Francesco
    Hu, Peter
    Fox, Patricia
    Medeiros, L. Jeffrey
    Estrov, Zeev
    Bueso-Ramos, Carlos E.
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [27] Identification of polymorphisms associated with susceptibility to therapy related MDS and AML
    Walgren, Richard
    McLaughlin, Edward
    Peterson, Elise
    Crosswhite, Michael
    Province, Michael
    McLeod, Howard
    Ley, Timothy
    Graubert, Timothy
    Morgan, Gareth
    BLOOD, 2007, 110 (11) : 12A - 13A
  • [28] RUNX1 mutations in MDS, s-AML, and de novo AML: differences in accompanying genetic alterations and outcome
    Stengel, Anna
    Kern, Wolfgang
    Meggendorfer, Manja
    Haferlach, Torsten
    Haferlach, Claudia
    LEUKEMIA & LYMPHOMA, 2019, 60 (05) : 1334 - 1336
  • [29] Therapy-related MDS and AML in acute promyelocytic leukemia
    Andersen, MK
    Pedersen-Bjergaard, J
    BLOOD, 2002, 100 (05) : 1928 - 1929
  • [30] In AML Secondary to MDS NPM1 Mutations Are Late Events, Less Frequent, and Associated with a Different Pattern of Molecular Mutations Than in De Novo AML
    Schnittger, Susanne
    Haferlach, Claudia
    Nadarajah, Niroshan
    Alpermann, Tamara
    Meggendorfer, Manja
    Perglerova, Karolina
    Kern, Wolfgang
    Haferlach, Torsten
    BLOOD, 2014, 124 (21)
12345